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The Permanent Atrial Fibrillation Outcome Study 
Using Dronedarone on Top of Standard Therapy 
(PALLAS) included patients aged over 65 years, who 
had at least 6-month history of permanent atrial 
fibrillation (AF) and risk factors for major vascular 
events.1,2 The latter comprised coronary artery disease, 
previous stroke or transient ischemic attack, symptomatic 
heart failure, which was defined as current New York 
Heart Association class II or III symptoms and admission 
to the hospital for heart failure in the previous year (but 
not in the most recent month), a left ventricular ejection 
fraction of <40%, peripheral arterial disease, or the 
combination of an age of 75 years or older, hypertension, 
and diabetes. They were randomized to receive either 
dronedarone at a dose of 400 mg twice daily or placebo. 
On July 5, 2011, the data monitoring committee 
recommended that the study be terminated for safety 
reasons. A total of 3236 patients had undergone 
randomization with median follow-up of 3.5 months. The 
investigators had defined as the first coprimary outcome: 
stroke, myocardial infarction, systemic embolism, or 
death from cardiovascular causes; and as a second 
coprimary outcome: unplanned hospitalization for a 
cardiovascular cause or death.  
The first coprimary outcome occurred in 43 patients 
receiving dronedarone and 19 receiving placebo (hazard 
ratio, 2.29; P = 0.002). There were 21 deaths from 
cardiovascular causes in the dronedarone group and 10 in 
the placebo group (hazard ratio-HR, 2.11; P = 0.046), 
including death from arrhythmia in 13 patients and 4 
patients, respectively (HR, 3.26; P = 0.03). Stroke 
occurred in 23 patients in the dronedarone group and 10 
in the placebo group (HR, 2.32; P = 0.02). Hospitalization 
for heart failure occurred in 43 patients in the 
dronedarone group and 24 in the placebo group (HR, 
1.81; P = 0.02). Thus, the authors concluded that 
dronedarone increased rates of heart failure, stroke, and 
death from cardiovascular causes in patients with 
permanent AF who were at risk for major vascular events 
and therefore this drug should not be used in such 
patients.  
In an earlier trial, the Antiarrhythmic Trial with 
Dronedarone in Moderate to Severe CHF Evaluating 
Morbidity Decrease (ANDROMEDA) study, after 
inclusion of 627 patients (310 in the dronedarone group 
and 317 in the placebo group), the trial was prematurely 
terminated again for safety reasons.3 During a median 
follow-up of 2 months, 25 patients in the dronedarone 
group (8.1%) and 12 patients in the placebo group (3.8%) 
died (HR in the dronedarone group, 2.13; P = 0.03). The 
excess mortality was predominantly related to worsening 
of heart failure — 10 deaths in the dronedarone group and 
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2 in the placebo group. The primary end point (composite 
of death from any cause or hospitalization for heart 
failure) did not differ significantly between the two 
groups; there were 53 events in the dronedarone group 
(17.1%) and 40 events in the placebo group (12.6%) (HR, 
1.38; P = 0.12). More increases in the creatinine 
concentration were reported as serious adverse events in 
the dronedarone group than in the placebo group. The 
authors concluded that in patients with severe heart 
failure and left ventricular systolic dysfunction, treatment 
with dronedarone was associated with increased early 
mortality related to the worsening of heart failure.  
The results of the above two studies diverge from 
those of earlier studies, like the ATHENA trial,4 but this 
does not offer any re-assurance on the use of dronedarone 
in patients with any risk factors. Dronedarone’s use has 
thus been restricted to maintenance of sinus rhythm in 
patients with paroxysmal AF and no underlying heart 
disease. It is contraindicated in patients with permanent 
AF and patients with current or previous episodes of heart 
failure or left ventricular systolic dysfunction, as 
detrimental effects of dronedarone have been documented 
in these groups of patients. In the ATHENA trial, patients 
with persistent AF also received the drug without 
apparent harm, but the definition of persistent and 
permanent AF is not that clear, and thus, great caution 
should be exercised in the persistent AF group, as well. 
Whether there will be a return of dronedarone for a 
second chance after this recent potentially fatal blow or 
setback remains doubtful. All these drawbacks taken 
together with the harmful effects of the drug on the liver 
with reported cases of liver damage necessitating liver 
transplantation make everybody heavily pensive and 
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